10-K: eXoZymes posts larger 2025 loss, flags going concern

eXoZymes reported a wider 2025 net loss, sharply lower cash, and a going concern warning while advancing its NCT program and winning new grants.

Summary

• Net loss was $9,158,734 for 2025, up 56.3% from $5,861,335 in 2024; net loss per share was $1.09 (basic and diluted).
• Total operating costs rose 63.8% to $9,716,471, driven by higher R&D ($3,706,991, +98.4%) and G&A ($6,009,480, +47.9%).
• Year-end cash and cash equivalents fell 68.7% to $3,039,343 from $9,719,310; working capital decreased to $2,372,687 from $9,487,137.
• Operating cash outflow improved but remained heavy at $(6,502,040) in 2025 versus $(8,505,650) in 2024.
• Management disclosed substantial doubt about the company’s ability to continue as a going concern absent additional financing.
• From inception through Dec 31, 2025, total grants awarded were $17,697,378 (2025: $4,058,367; 2024: $1,048,302).
• 2025 grants and awards included a DoD BioMADE cost-share (~$1,000,000, awarded Oct 2024), an NIH BioClick grant ($283,805, Mar 2025), and an NSF CFIRE subaward via Georgia Tech ($3,000,000 share, Jul 1, 2025).
• NCT program advanced to pilot scale with >99% reaction yield, >99% purity, 6x faster production cycles than conventional methods, and successful tech transfer; commercialization to proceed via subsidiary NCTX using CMOs.
• Shares outstanding were 8,406,681 at Dec 31, 2025 (8,478,992 as of Mar 29, 2026); MDB Capital Holdings LLC beneficially owned 47.63% as of Mar 30, 2026.
• Material weaknesses in internal control over financial reporting were identified (inadequate design of policies/procedures and testing), and disclosure controls were deemed not effective as of Dec 31, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views the widened loss, steep cash decline, going concern warning, and control weaknesses as materially negative, partially offset by grant wins and NCT pilot-scale progress.

Positives

• NCT program reached pilot-scale readiness with >99% reaction yield and >99% food/pharma-grade purity; successful external tech transfer and SOPs completed.
• Captured new non-dilutive funding: NIH BioClick grant of $283,805 (Mar 2025) and an NSF CFIRE subaward via Georgia Tech for $3,000,000 (Jul 1, 2025).
• Continuing government support for isobutanol pathway (DoD BioMADE cost-share ~ $1,000,000 awarded Oct 2024).
• Operating cash burn improved year over year (operating cash outflow of $(6.5)M in 2025 vs. $(8.5)M in 2024).
• R&D progress and commercialization plan via an asset-light CMO model (NCTX) targeting a near-term nutraceutical launch with potential pharmaceutical derivatives.
• No material legal proceedings and no reportable cybersecurity incidents in 2025.

Negatives

• No revenue and a larger 2025 net loss of $9.16M (+56.3% y/y); operating costs rose 63.8% to $9.72M.
• Cash fell 68.7% to $3.04M; working capital dropped by $7.11M year over year to $2.37M.
• Going concern warning due to anticipated funding shortfalls and pre-revenue status.
• Material weaknesses in internal control over financial reporting; disclosure controls deemed not effective.
• Significant shareholder concentration: MDB Capital Holdings LLC owned 47.63% as of Mar 30, 2026, which can influence corporate actions.
• Execution and regulatory risks remain for nutraceutical/pharmaceutical pathways; NCT not yet FDA-evaluated.

Risks

• Going concern uncertainty; inability to secure additional capital could force curtailment of operations.
• Pre-revenue status with no assurance of commercialization, profitability, or continued grant funding.
• Financing risk and potential dilution from future equity or debt raises; no identified sources of funding currently.
• Scale-up and manufacturing risks; reliance on CMOs and partners could delay timelines or increase costs.
• Regulatory risks for nutraceutical and pharmaceutical markets, including GRAS/NDIN outcomes, potential reclassification of cannabinoids, and drug development requirements.
• Intellectual property risks, including potential infringement claims, challenges to licensed or owned IP, and dependence on UC Regents license milestones and royalties.
• Competitive pressures from synthetic biology and cell-free peers and large incumbents; potential skepticism of novel cell-free biocatalysis approaches.
• Operational concentration risk due to a single facility; disruptions could halt R&D and pilot work.
• Internal control material weaknesses may impact financial reporting reliability.
• Market and listing risks including potential Nasdaq non-compliance, stock volatility, and low float dynamics.

Future Outlook

Management plans a 2026–2027 focus on low-volume, high-value nutraceuticals with pharmaceutical potential, led by an NCT launch via NCTX using a capital-light CMO model, while continuing government-supported isobutanol work and pursuing partnerships, spin-outs, JVs, and licensing; management also notes the need for additional capital to fund operations and mitigate going concern uncertainty.

Management Comments

• Management believes the exozyme platform is differentiated and can enable scalable, greener production of small molecules versus traditional extraction, petrochemical synthesis, or cell-based SynBio.
• The company believes nutraceutical-first commercialization reduces risk and accelerates time to market, with potential for future pharmaceutical derivatives.
• There remains substantial doubt about the ability to continue as a going concern without additional financing.

Industry Context

StockSavvy.ai notes that eXoZymes is positioning cell-free multi-enzyme systems as a successor to traditional synthetic biology approaches, amid a market where peers like Debut Biotech and Solugen also promote cell-free advantages, and incumbents (e.g., Codexis) demonstrate multi-enzyme applications; the strategy aligns with rising interest in sustainable biomanufacturing but faces typical pre-revenue execution and funding hurdles.

Comparison to Industry Standards

• Relative to Codexis (enzyme engineering with commercial partnerships), eXoZymes remains pre-revenue and earlier in commercialization, increasing execution and funding risk versus established peers.
• Compared with cell-free peers (e.g., Debut Biotech, Solugen), eXoZymes’ NCT pilot data (>99% yield/purity; faster cycles) is promising but still must translate to commercial scale and repeatability.
• In biofuels, companies like Gevo and Butamax target market-scale fuels; eXoZymes’ isobutanol effort is grant-supported and earlier-stage, implying longer timelines to revenue relative to industry incumbents.
• Against broader SynBio firms that struggled with cell-based scaling, eXoZymes’ cell-free approach may mitigate toxicity and yield issues, but it must demonstrate durable economics and supply chain readiness to match industry benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings as of December 31, 2025.

Related Party Transactions

• Payable to MDB Capital Holdings LLC of $5,330 outstanding at December 31, 2025 (non-interest bearing).
• Related party debt forgiveness of $147,103 recorded in 2025.
• SAFE conversion on November 11, 2024: $800,000 (MDB Capital Holdings LLC and executive Paul Opgenorth) converted into 125,001 common shares.
• MDB Capital Holdings LLC beneficially owned 47.63% of common stock as of March 30, 2026; overlapping directors and chairman noted.

Stakeholder Impact

• Shareholders face dilution risk from potential future equity raises and significant insider ownership concentration.
• Employees benefit from expanded equity incentive plans but face uncertainty from going concern status and cost controls.
• Customers/partners may see timelines depend on successful CMO engagements and financing availability.
• Suppliers/CMOs could gain from scale-up activity, contingent on funding and demand.
• Creditors currently limited; payables rose with supplier-financed activity and bonus accruals.

Next Steps

• Advance NCT commercialization via NCTX with a capital-light CMO model (formulation, scale-up, supply chain readiness).
• Pursue additional grants and strategic partnerships, spin-outs, JVs, and licensing to monetize the platform.
• Continue government-supported isobutanol program and cell-free platform development.
• Address internal control material weaknesses and enhance testing of controls.
• Evaluate and potentially utilize shelf registration and/or other financing options to extend runway.

Key Dates

Recommendation

The widened loss, steep cash decline, going concern warning, and control weaknesses materially elevate risk, while commercialization remains pre-revenue and capital dependent; despite encouraging NCT pilot metrics and grant support, the immediate risk/reward skews negative until funding runway and revenue visibility improve.

Keywords

eXoZymes, cell-free biocatalysis, exozymes, N-trans-caffeoyltyramine, NCT, nutraceutical, pharmaceutical, isobutanol, biofuels, NSF CFIRE, NIH BioClick, DoD BioMADE, CMO, going concern, synthetic biology